We serve Chemical Name:5-bromo-4-chloro-2-hydroxybenzoic acid CAS:142167-38-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:5-bromo-4-chloro-2-hydroxybenzoic acid
CAS.NO:142167-38-2
Synonyms:5-Bromo-4-chlorosalicylic acid;5-bromo-4-chloro-2-hydroxy-benzoic Acid
Molecular Formula:C7H4BrClO3
Molecular Weight:251.46200
HS Code:2918290000
Physical and Chemical Properties:
Melting point:N/A
Boiling point:370.8ºC at 760mmHg
Density:1.956g/cm3
Index of Refraction:1.663
PSA:57.53000
Exact Mass:249.90300
LogP:2.50630
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 5-Bromo-4-chlorosalicylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-bromo-4-chloro-2-hydroxy-benzoic Acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-bromo-4-chloro-2-hydroxy-benzoic Acid Use and application,5-Bromo-4-chlorosalicylic acid technical grade,usp/ep/jp grade.
Related News: The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said. 5-bromo-4-chloro-2-hydroxybenzoic acid manufacturer We are pleased that intravenous rigosertib will be made compliantly available to suitable patients with higher-risk MDS through their physicians in designated countries. 5-bromo-4-chloro-2-hydroxybenzoic acid supplier Britons being brought from Wuhan to the UK are being placed in quarantine at Arrowe Park Hospital in the Wirral, northwest England, Raab said. 5-bromo-4-chloro-2-hydroxybenzoic acid vendor The FDA has granted so-called accelerated approval in more than 250 instances since 1992, mainly for rare diseases or small patient populations that have had no effective treatments available to them. In these cases, the agency requires that drugmakers conduct additional clinical trials to prove their therapy works, or face withdrawal from the market. 5-bromo-4-chloro-2-hydroxybenzoic acid factory The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said.
